Highlight
Berberine, administered orally for 2 years, significantly reduces colorectal adenoma recurrence after endoscopic polypectomy with sustained effects lasting over 6 years post-treatment.
Low recurrence rates (34.7% vs 52.1%) and reduced colorectal neoplasm incidence (63.4% vs 71.0%) indicate durable and clinically meaningful chemopreventive benefit.
Safety profile is favorable, and the agent offers a cost-effective, accessible option for secondary prevention of colorectal neoplasms.
